Regeneron Pharmaceuticals, IncNasdaq: REGN
Health Care · Biotechnology
$610.51
-4.99%
Vol: 64K
Research Digest
Monday, June 15, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Regeneron remains under pressure after Phase 3 melanoma trial of fianlimab plus Libtayo failed primary endpoint versus Keytruda, prompting analyst price target cuts.Negative▶
Regeneron shares fell more than 11% on May 18, 2026 after the company disclosed that the Phase 3 trial of fianlimab plus Libtayo in first-line metastatic melanoma missed its primary endpoint versus Merck's Keytruda, a setback for what management had previously flagged as a potential blockbuster. In response, Wolfe Research lowered its price target to $860 from $900 and Evercore ISI cut to $825 from $875. On the positive side, Regeneron and Sanofi presented Phase 4 REMODEL data showing Dupixent improved esophageal function in eosinophilic esophagitis, and the company announced a strategic collaboration with Parabilis Medicines to develop Antibody-Helicon Conjugates. Several law firms including Levi & Korsinsky and SueWallSt have opened shareholder investigations following the trial-related decline. REGN traded near $643 as of May 20, 2026.
May 20Regeneron shares dropped over 10% on May 18 after its Phase 3 fianlimab+Libtayo melanoma trial failed vs Keytruda, drawing Citi downgrade and shareholder investigations.Negative▶
Regeneron Pharmaceuticals shares plunged more than 10% at the open on May 18, 2026, after the company disclosed over the weekend that its Phase 3 melanoma trial of fianlimab combined with Libtayo failed to beat Keytruda on its primary endpoint. Citi downgraded the stock to Hold and several analysts cut price targets following the readout. Multiple law firms, including Levi & Korsinsky and SueWallSt, have launched shareholder investigations into whether Regeneron made misleading statements about the trial's expected outcome. On May 18, Regeneron also announced a $125M strategic research collaboration with Parabilis Medicines for Helicon peptide therapeutics. The company declared a $0.94 dividend with an ex-date of May 20.
May 19Regeneron shares dropped ~11-12% on May 18, 2026 after its fianlimab-cemiplimab combo failed to beat Merck's Keytruda in a Phase 3 melanoma trial, triggering at least 10 broker target cuts; separately, REGN signed a partnership worth up to $2.2B with Parabilis Medicines.Negative▶
In a 1,546-patient Phase 3 melanoma study, Regeneron's high-dose fianlimab combination with cemiplimab (Libtayo) extended median progression-free survival by about five months vs. Merck's Keytruda but missed statistical significance, dealing a blow to REGN's oncology strategy. Shares fell roughly 11-12% in premarket/morning trade on May 18, 2026, to around $618, with at least 10 brokerages cutting price targets - Citi downgraded to Neutral from Buy and trimmed its target to $700 from $900, and RBC Capital cut to $707, while BofA reiterated Buy with $860 and Jefferies held its Buy. Separately, Regeneron disclosed a partnership with privately held Parabilis Medicines worth up to $2.2 billion in milestone payments for hard-to-reach disease targets, and confirmed a $0.94 cash dividend with an ex-date of May 20. The combination matters because oncology was a key long-term growth pillar beyond Eylea and Dupixent, and another pipeline miss raises questions about diversification. The bear case is intensifying competitive pressure from Keytruda plus broader pipeline execution risk; the partial offset is the Parabilis deal, ongoing Dupixent strength, and a fresh $3B buyback authorized in late April.
May 18Regeneron shares plunged ~12% on May 18 after Phase 3 fianlimab melanoma trial failed to beat Merck's Keytruda, dealing a major pipeline setback.Negative▶
On May 18, 2026 Regeneron announced its late-stage Phase 3 trial of fianlimab (LAG-3 inhibitor) in combination for first-line unresectable/metastatic melanoma failed to beat Merck's Keytruda, sending shares down ~12%. The setback adds to a string of recent challenges and follows weaker stock performance with shares down ~7% over the past month and ~13% over three months, closing near $698.25 in mid-May. On May 8 Regeneron was named to the Dow Jones Best-in-Class World Index for the seventh consecutive year, and on May 15 the 2026 Regeneron International Science and Engineering Fair distributed $7M in student awards. Bank of America Securities reiterated Buy on May 8. Consensus from 23 analysts remains Buy with an average PT of $842.13 (implying ~17% upside) heading into the trial readout, though estimates are likely to be revised post-failure.
May 15Regeneron's $0.94 dividend goes ex on May 20 following FDA approval for gene therapy Otarmeni and a $9B U.S. R&D commitment via White House pricing deal.Positive▶
Regeneron's $0.94 quarterly cash dividend goes ex-dividend on May 20, 2026. The company recently won FDA approval for Otarmeni, the first gene therapy for a rare genetic form of deafness, and is offering it free in the U.S. Regeneron struck a drug pricing agreement with the White House, gaining relief from government pricing mandates in exchange for $9B in U.S. R&D and manufacturing investment through 2030. Q1 2026 revenue grew 19% with Dupixent up 33% to $4.9B and Eylea HD up 52%. The company also authorized a new $3.0B buyback. Analyst consensus Buy with $842 target; risk: regulatory and competitive dynamics in eye-care biosimilars.
May 14Regeneron's Dupixent Phase 4 EoE trial succeeds while Bank of America upgrades stock on improving fundamentals and 2026 catalystsPositive▶
Regeneron reported in May 2026 that Dupixent (dupilumab) demonstrated improved esophageal function in eosinophilic esophagitis in a Phase 4 trial, expanding the franchise's clinical profile. Bank of America upgraded the stock citing improving fundamentals and 2026 catalysts, joining a 23-analyst Buy consensus with an $842 average price target (about 17% upside from $721). The recently FDA-approved Otarmeni gene therapy for OTOF-related hearing loss continues to gain attention as the first neurosensory gene therapy, offered free to U.S. patients. A $0.94 dividend ex-date is May 20, and the company presented at the BofA Healthcare Conference on May 12. Q1 revenue rose to $3.4-3.6 billion, up 8-19% YoY driven by Eylea HD and Dupixent. The risk is Eylea biosimilar competition and the free-of-charge launch model for Otarmeni limiting near-term revenue.
May 13Regeneron and Lilly advance obesity combo trial as tirzepatide Phase 3 reaches completion, building on May 5 Dupixent Phase 4 EoE results.Mixed▶
On May 7, Eli Lilly and Regeneron advanced their obesity combination bet as a key tirzepatide trial reached completion - a major catalyst for the combined obesity-treatment opportunity. On May 5, Regeneron and Sanofi presented Dupixent Phase 4 trial results showing improved esophageal function in eosinophilic esophagitis. The stock has rebounded 0.93% week-over-week despite being down 7.02% over the past month following Q1 results showing revenue of $3.6B and net income of $727M. The company authorized a fresh $3B share buyback after completing $2.31B prior repurchase, and declared a $0.94 dividend (ex-date May 20). Analyst views split: Guggenheim raised PT to $995, RBC Capital lowered to $762.
May 12Regeneron presents at BofA Healthcare Conference May 12 as Bank of America resets price target amid biosimilar concerns and Otarmeni gene therapy launch.Mixed▶
Regeneron is participating in the BofA Securities Health Care Conference 2026 on May 12, where management will discuss its pipeline of nearly 50 candidates. Bank of America issued a fresh price-target reset, reshaping the narrative around the stock as biosimilar competition for Eylea looms in H2 2026. The recently FDA-approved Otarmeni gene therapy for OTOF-related hearing loss is being offered free to U.S. patients. Dupixent posted positive Phase 4 esophageal function data in EoE. Shares trade near $721 (down ~10% over the past month) following Q1 EPS of $9.47 (5.6% beat) and revenue of $3.6B (+19% YoY). Insider Arthur Ryan disclosed share sales.
May 11Regeneron's Dupixent showed improved esophageal function in a Phase 4 EoE trial on May 5, while shares trade near $721 with a $3 billion buyback authorization underpinning capital return.Positive▶
Regeneron Pharmaceuticals announced on May 5 that Dupixent (dupilumab) demonstrated improved esophageal function in a Phase 4 eosinophilic esophagitis trial, expanding the franchise's clinical case. The company was named to the Dow Jones Best-in-Class World Index for the seventh consecutive year, and confirmed it will provide its newly approved Otarmeni gene therapy for genetic hearing loss free in the U.S. (FDA accelerated approval April 22-23). Q1 2026 EPS of $9.47 beat estimates by 5.57% on revenue of $3.6 billion (+19% YoY), with Sanofi collaboration revenue at $1.6 billion (+42% profit share). The Board authorized a new $3 billion buyback. Shares traded near $721 on May 7 but are down ~9.8% over the past month. Regeneron presents at the BofA Healthcare Conference May 12. Risk is post-rally consolidation and competitive Eylea dynamics.
May 8Regeneron reports Q1 2026 revenue of $3.61B (+19% YoY) beating consensus, named to Dow Jones sustainability index for 7th yearPositive▶
Regeneron delivered strong Q1 2026 with revenue of $3.61B (vs. $3.47B consensus, 3.8% beat) representing 19% YoY growth. Adjusted EPS of $9.47 beat $8.90 forecast (6.4% beat). Dupixent global net sales (via Sanofi) increased 33% to $4.9B. Dupixent showed improved esophageal function in Phase 4 EoE trial on May 5. Named to Dow Jones Best-in-Class World Index for 7th consecutive year as one of only 8 biotechnology companies globally included. Board authorized $3B share repurchase program. Ex-dividend date of May 20 with dividend of $0.94. Margin decline attributed to R&D investments, manufacturing interruption in Ireland, and new product launch costs. Company participating in BofA and Goldman Sachs healthcare conferences in May-June.
May 6Regeneron reports strong Q1 2026 with $3.6B revenue and FDA approvals for Dupixent and gene therapy; authorizes $3B buyback.Mixed▶
Regeneron reported Q1 2026 revenue of $3.6 billion and non-GAAP EPS of $9.47, beating Wall Street expectations. The FDA granted accelerated approval for Otarmeni, a free in vivo gene therapy for OTOF-related hearing loss, with the company pledging free treatment in the U.S. Dupixent was expanded to children aged 2-11 with chronic spontaneous urticaria. The company signed an agreement with the U.S. Government to help lower drug costs and authorized a new $3 billion share repurchase program. Despite strong operational results, shares declined 0.8% recently, down 6.7% over the past week and 9.8% over the past month, suggesting valuation concerns or profit-taking.
May 5Regeneron reports strong Q1 2026 but shares fall on Eylea sales and pipeline concernsMixed▶
Regeneron reported strong Q1 2026 earnings with 19% revenue growth to $3.6B and $9.47 adjusted EPS, but shares fell on Eylea sales concerns and pipeline execution risks. Company announced $3B buyback program. FDA approved Otarmeni gene therapy for genetic hearing loss and EYLEA HD with up to 5-month dosing intervals. Stock down 0.8% past day, 6.7% past week, 9.8% past month but up 16.5% YoY.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| ABBVABBVIE | $222.45 | +3.70% | +2.4% | 13.2x | 0.30 | $379.0B |
| AMGNAMGEN | $353.95 | +4.90% | +4.0% | 14.4x | 0.43 | $182.2B |
| GILDGILEAD | $124.38 | -4.69% | +0.6% | 13.6x | 0.33 | $162.0B |
| VRTXVERTEX | $445.91 | +2.85% | -0.7% | 20.2x | 0.30 | $110.0B |
| REGNREGENERON | $610.51 | -4.99% | +2.0% | 11.9x | 0.30 | $67.4B |
| BIIBBIOGEN | $197.70 | +4.34% | -1.3% | 11.4x | 0.20 | $28.0B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.